

Company Report

NEOSTEM, INC.

Rob Goldman
rob@goldmanresearch.com
 Aaron Schweitzer
aaschweitzer@yahoo.com

July 29, 2010

NEOSTEM, INC. (NYSE:AMEX – NBS- \$1.94)

Price Target: \$4.50

Rating: Speculative Buy

COMPANY SNAPSHOT

NeoStem Inc. is an international biopharmaceutical company engaged in adult stem cell collection and storage, the development of stem cell-based therapies, and generic pharmaceuticals in China. NeoStem's network of adult stem cell collection centers in the U.S. and Asia enable adults to donate and store their own stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ technology which has shown to have several physical characteristics typically found in embryonic stem cells. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China.

KEY STATISTICS

Price as of 7/28/10	\$1.94
52 Wk High – Low	\$3.50 – 1.26
Est. FD Shares Out.	56.8M
Market Capitalization	\$110.2M
3 Mo Avg Vol	408,000
Exchange	NYSE: Amex

COMPANY INFORMATION**NeoStem, Inc.**

420 Lexington Avenue, Suite 450
 New York NY 10170
 212-514-4180
www.neostem.com

Kalle Ahl CFA, Investor Relations
 646-833-3417
Kalle.ahl@ccgir.com

INVESTMENT HIGHLIGHTS

NeoStem is a pioneer in the ground-breaking stem cell market. The Company is a leader in stem cell banking, and is an emerging provider of stem cell operations through its worldwide exclusive license to cutting-edge VSEL™ platform technology. According to leading research firm Markets and Markets, the global stem cell products market is expected to reach \$88 billion in 2014.

The Company has positioned itself as a diverse biopharmaceutical firm in terms of business lines, stem cell operations and geography. NeoStem generates meaningful revenue from its 51%-owned generics pharmaceutical subsidiary Suzhou Erye, and is engaged in the provision of stem cell services and technology in the U.S. and China.

NeoStem's stem cell business and technology models have received "a blessing" from the Catholic Church via joint ventures with the Vatican Pontifical Counsel. This landmark relationship includes initiatives such as up to \$1M in funding for stem cell therapy research as well as market education and awareness.

NeoStem has already begun to successfully leverage its Suzhou Erye operations and we expect the Company to ride the huge wave of growth in the Chinese pharmaceuticals market. The industry is expected to triple in size by 2014 and become the 3rd largest pharmaceutical market the world.

This undervalued company is a leader in 2 of the most exciting and fastest-growing segments of the entire health care sector. Plus, its diversified business approach lowers the risk profile as compared to other stem cell plays. Based on our sum-of-the-parts valuation, we project that the China pharma operations could be worth nearly \$2.80 a share and the stem cell business worth a conservative \$1.70 per share. This is based on publicly-traded generic comparables and stem cell company peer valuations. We rate the stock a Speculative Buy with a \$4.50 six-month price target.

NEOSTEM, INC. (NYSE: AMEX: NBS)

Analyst: Robert Goldman

Rob Goldman has 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This *Opportunity Research* report was prepared for informational purposes only. *Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* product reflects the Firm's internally generated stock ideas while the *Opportunity* product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the *Opportunity* format may have a higher risk profile, they typically offer greater upside as well. *Goldman Small Cap Research* has been compensated by a related party, in the amount of \$10,000 for a three month subscription service. The Firm does not accept any equity compensation. All information contained in this report was provided by the Company. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com